Osprey Medical Inc. announced that Dr. Roxana Mehran will be the Principal Investigator (PI) of the AVERT Trial. This trial will evaluate the company's AVERT(TM) System for a marketing claim expansion to include 'reduction of Contrast Induced Nephropathy (CIN)' for patients undergoing angiogram or stenting procedures. Dr. Mehran is a U.S. interventional cardiologist with world-recognized expertise in the area of CIN.

She is Professor of Medicine and Director of Interventional Cardiovascular Research at Mount Sinai Hospital in New York. Dr. Osprey Medical also announced that Dr. Gregg Stone will serve as Chairman of the AVERT Trial's Steering Committee, which provides strategic direction and oversight of publications. Dr. Stone is Professor of Medicine and the Director of Cardiovascular Research and Education at New York-Presbyterian Hospital/Columbia University Medical Center.

He is also the Co-Director of Transcatheter Cardiovascular Therapeutics (TCT).